Our Services
Medical Information
Helpful Resources
Published on: 7/2/2026
Routine bloodwork offers critical insight into how your body responds to GLP-1 therapy, helping guide dose adjustments, manage side effects, and drive lasting improvements in blood sugar, weight, and overall health.
Key panels to monitor include:
Testing is typically recommended before starting GLP-1s, at 3 months, and every 6–12 months thereafter. Warning signs like persistent nausea, abdominal pain, or unusual fatigue warrant immediate follow-up.
If you're experiencing symptoms while on GLP-1 therapy—or wondering whether new changes are normal—don't guess. A free, instant, online symptom check can help you identify what's going on, flag anything urgent, and clarify your next steps in minutes. It's a smart, no-cost way to bring focused questions to your next appointment and take control of your treatment journey.
Reviewed for medical accuracy: 07/02/2026
Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the management of type 2 diabetes and obesity. By mimicking a natural gut hormone, GLP-1 medications improve blood sugar control, curb appetite and support weight loss. But to get the most benefit—and to stay safe—regular health metric monitoring is essential. Bloodwork offers a clear window into how your body is responding, helping you and your care team make smart decisions along the way.
Routine lab tests help you and your provider keep a close eye on vital systems. Here are the most important panels to request:
Frequency may vary based on your starting health status and how long you've been on therapy. A common schedule:
• Baseline labs before starting GLP-1
• 3 months after initiation or dose change
• 6- to 12-month intervals once stable
• More often if you have chronic kidney disease, liver issues or other health conditions
Work with your healthcare provider to tailor the schedule to your needs.
• Keep copies of all lab results in a dedicated folder or digital health app.
• Bring recent results to every doctor's appointment.
• Schedule blood draws in the morning, fasting if required.
• Stay hydrated—proper hydration helps get accurate kidney and electrolyte readings.
• Share any new or worsening symptoms, even if lab tests look normal.
While bloodwork is the gold standard for most safety monitoring, pay attention to symptoms between tests:
• Persistent abdominal pain or nausea (could signal pancreatic irritation)
• Unusually fatigue or muscle weakness (may relate to blood sugar swings or electrolyte changes)
• Jaundice or dark urine (possible liver stress)
• Shortness of breath or swelling (could reflect kidney or heart issues)
If you experience any of these, use this Medically approved LLM Symptom Checker Chat Bot to understand what your symptoms might mean before your next appointment, or speak to your doctor right away if urgent.
Successful GLP-1 therapy is built on a foundation of collaboration:
• You track symptoms, diet, exercise and medication adherence.
• Your provider interprets lab results and adjusts therapy.
• Lab services deliver timely, accurate numbers for informed decision-making.
Open communication ensures you stay on track toward your goals while minimizing risks.
GLP-1 therapies offer compelling advantages:
• Better glycemic control
• Significant weight loss
• Potential cardiovascular protection
But no medication is free of side effects. Regular health metric monitoring keeps those risks in check, so you can reap the benefits without unwelcome surprises.
Most importantly, always speak to a doctor about any symptoms or lab values that feel serious or life-threatening. Regular bloodwork is your roadmap to GLP-1 success—use it to stay informed, empowered and safe on your health journey.
(References)
* Xu Y, Huang C, Fu J, Chen X, Liang Y, Xiao J, Lu W, Luo X. Safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023 Aug 17;14:1229712. PMID: 37648356.
* Lytvyn Y, Ng K, Perkins BA, Cherney DZI. Renal effects of GLP-1 receptor agonists: from clinical trials to real-world evidence. Nat Rev Nephrol. 2022 Feb;18(2):107-124. PMID: 34947937.
* Li CJ, Yu Q, Zhai M, Han F, Yu P, Lu X, Wen W, Yu T. Adverse events of glucagon-like peptide-1 receptor agonists in type 2 diabetes: An updated systematic review and meta-analysis. Diabetes Metab Res Rev. 2022 Sep;38(6):e3557. PMID: 35760824.
* Vasilevski V, Sotiroski T, Ilievska B, Stoshevski P, Krstikj M. GLP-1 Receptor Agonists and Metabolic Control in Type 2 Diabetes Mellitus: A Review of Clinical Efficacy. Endocrines. 2024 Feb 13;5(1):164-180. PMID: 38392189.
* Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos K, Andreadis P, Liakos A, Jeon JY, Matthews DR, Danese MD, Weiss R, Khunti K, Ntoumpas M, Tziomalos K. Cardiovascular and renal outcomes of GLP-1 receptor agonists in patients with overweight or obesity and without diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2023 Oct;11(10):734-743. PMID: 37626938.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.